SCHEMBL5565577

SCHEMBL5565577

CCOc1cc2ncnc(Nc3cccc(O)c3)c2cc1OCC

nearest known ligand 0.78

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 2/20 0.78
FLT1 P17948 2/20 0.78
RET P07949 1/20 0.78
CDK2 P24941 1/20 0.78
PIK3R1 P27986 1/20 0.78
EPHB2 P29323 1/20 0.78
KIF5B P33176 1/20 0.78
KDR P35968 1/20 0.78
TTBK1 Q5TCY1 1/20 0.78
EGFR P00533 11/20 0.77
NOD1 Q9Y239 1/20 0.76
FBP1 P09467 5/20 0.74
ERBB2 P04626 2/20 0.73
ERBB4 Q15303 2/20 0.73
RAF1 P04049 1/20 0.64
BRAF P15056 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30249695 0.88 KDR (1.00) FGFR1FLT1RETCDK2PIK3R1
SCHEMBL1180103 0.88 KDR (1.00) FGFR1FLT1RETCDK2PIK3R1
SCHEMBL29435034 0.88 KDR (1.00) FGFR1FLT1RETCDK2PIK3R1
Hydrochloric Acid SCHEMBL30433676 0.86 NOD1 (1.00) FGFR1FLT1RETCDK2PIK3R1
SCHEMBL2100996 0.86 EGFR (0.77) EGFRFBP1ERBB2ERBB4
SCHEMBL4477758 0.86 EGFR (0.77) RETKDREGFRFBP1ERBB2
SCHEMBL7119658 0.85 FBP1 (1.00) EGFRFBP1ERBB2ERBB4
SCHEMBL5606140 0.85 FBP1 (1.00) EGFRFBP1ERBB2ERBB4RAF1
SCHEMBL3008965 0.85 FBP1 (1.00) EPHB2KDREGFRFBP1ERBB2
Hydrochloric Acid SCHEMBL3258223 0.84 EGFR (0.75) EGFRFBP1ERBB2ERBB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US claimed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP claimed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO claimed
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US disclosed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP disclosed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections IRF3, PML, TPMT FGFR1 2809/4885FLT1 2348/4885RET 2776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.